|
|||||
|
|
Fucosyl-GM1 in small-cell lung cancer. A comparison with the tumour marker neuron-specific enolase |
|
| Authors: | Drivsholm, L. Vangsted, A. Pallesen, T. Hansen, M. Dombernowsky, P. Hirsch, F. Hansen, H. H. |
| Affiliation: | 1Department of Oncology, Rigshospitalet Copenhagen, Denmark 2The Wallenberg Laboratory, University of Lund Sweden 3School of Dentistry, University of Copenhagen Hillerød 4Department of Oncology Hillerød 5Department of Oncology, Herlev Hospital Denmark 6Department of Oncology, Bispebjerg Hospital Denmark |
| Abstract: | BACKGROUND:: Recently, the ganglioside Fucosyl-GM1 (FucGM1) has been describedas a possible new tumour marker for small-cell lung cancer (SCLC).FucGM1 has been detected in 75% to 90% of SCLC tumours by immunohis-tochemicalanalysis and in about 50% of sera from SCLC patients. Neuron-specificenolase (NSE) is a glycolytic enzyme which is expressed in themajority of SCLC tumours and patient sera. PATIENTS AND METHODS:: Sera from 156 patients with SCLC were analyzed for FucGM1 witha scintillation proximity assay (SPA), which is a simple andsensitive analysis. Sera were analyzed before the initiationof chemotherapy, and twenty patients were monitored during andafter treatment. The concentration of FucGM1 was compared tothe tumour marker NSE and related to clinical data and survival. RESULTS:: Sixty-three per cent of the patients were positive for FucGM1.The concentrations did not correlate with NSE or clinical dataincluding stage of disease, organ site of metastases or ABOblood group status. Nor did the expression of FucGM1 correlatewith survival. As a monitor of clinical response, a correlationwas found in 8 out of 20 patients. Eighty-four per cent of thepatients were positive for NSE; and 97% were positive for eitherFucGM1 or NSE. CONCLUSION:: We conclude that FucGM1 does not have a clinical role as a tumourmarker for patients with SCLC at diagnosis or during treatment. Fucosyl-GM1, NSE, SCLC, tumour marker |
| Keywords: | |
| 本文献已被 Oxford 等数据库收录！ | |